Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

'Broccoli drug' may treat osteoarthritis
broccoli
The beneficial effects of broccoli are due to sulforaphane, a compound released during digestion.

Positive results for new drug tested at the RVC

A chemical found in broccoli could offer a treatment for osteoarthritis, after a new drug has been successfully trialled for the first time at the Royal Veterinary College (RVC).

Eating cruciferous vegetables such as sprouts, cabbages and particularly broccoli has been found to ease the symptoms of osteoarthritis. However, patients would have to eat a substantial amount each day to see any real benefits.

The advantages of broccoli are due to sulforaphane, a compound released from the vegetable during digestion, which blocks certain enzymes that destroy joint cartilage. It also obstructs processes that cause the inflammation linked to osteoarthritis.

It had proved impossible to manufacture sulforaphane into a regular pill as it is an unstable molecule.

However, working alongside the RVC, UK pharmaceutical company Evgen Pharma has developed a stable, synthetic version of the compound and incorporated it into a new medicine called Sulforadex (SFX-01). Just a single dose of this medication provides as much sulforaphane as 2.5kg of broccoli.

Osteoarthritis affects nearly nine million people in the UK, costing the NHS over £5 billion a year. Other than pain relief and joint replacement, there is currently no effective treatment or cure. The RVC's professor of skeletal dynamics, Andrew Pitsillides said there is "massive" potential for SFX-01.

For the first time, the product has been trialled by the RVC using live laboratory mice prone to osteoarthritis.

Osteoarthritic mice treated with SFX-01 were shown to have substantially improved movement, gait balance and bone architecture, compared with the control group that did not receive treatment.

“These initial results are very positive for such an experiment and we have convinced ourselves that sulforaphane is a promising agent for the treatment of osteoarthritis," said Prof Pitsillides.

“However, the clinical development of sulforaphane has been held back by the fact that it is inherently unstable. Thus, SFX-01 is a major advance in this area.”

Further pre-clinical and then human clinical trials are needed now that the product is seen as a viable treatment for the painful joint condition.

Human trials are already underway to further investigate the anti-cancer and anti-inflammatory properties of sulforaphane.

Become a member or log in to add this story to your CPD history

Huge spike in ‘designer’ dogs going into rescue

News Story 1
 The RSPCA has reported a huge spike in the number of ‘designer’ dogs arriving into its care.

Figures published by the charity show there has been a 517 per cent increase in the number of French bulldogs arriving into its kennels. During that time, the charity has also seen an increase in dachshunds, chihuahuas, and crossbreeds.

RSPCA dog welfare expert Lisa Hens said: “We know that the breeds of dog coming into our care often reflect the trends in dog ownership in the wider world and, at the moment, it doesn’t get more trendy than ‘designer’ dogs like French bulldogs and Dachshunds."

 

Click here for more...
News Shorts
Withdrawal period increased for Closamectin pour-on

The withdrawal period for Closamectin pour-on solution for cattle has been increased from 28 days to 58 for meat and offal.

Closamectin treats roundworms, late immature to adult fluke (from seven weeks), mange mites and lice.

Norbrook Laboratories Ltd said the change would take effect immediately. Customers are being offered practical support to inform end users.

The change meets industry requirements to reduce the amount of residue going into food and the environment. It has been approved by the Veterinary Medicines Directorate and an updated summary of product characteristics will be available on the website.